Disease understanding in patients newly diagnosed with atrial fibrillation.


Journal Article

OBJECTIVE: To describe self-reported disease understanding for newly diagnosed patients with atrial fibrillation (AF) and assess (1) how disease understanding changes over the first 6 months after diagnosis and (2) the relationship between patient understanding of therapies at baseline and treatment receipt at 6 months among treatment-naïve patients. METHODS: We analysed survey data from SATELLITE (Survey of Patient Knowledge and Personal Priorities for Treatment), a substudy of patients with new-onset AF enrolled in the national Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT) II registry across 56 US sites. Patients were surveyed at the baseline and 6-month follow-up clinic visits using Likert scales. RESULTS: Among 1004 baseline survey responses, patients' confidence in their understanding of rhythm control, ablation, anticoagulation and cardioversion was suboptimal, with 'high' understanding ranging from 8.5% for left atrial appendage closure to 71.3% for rhythm therapy. Of medical history and demographic factors, education level was the strongest predictor of reporting 'high' disease understanding. Among the 786 patients with 6-month survey data, significant increases in the proportion reporting high understanding were observed (p<0.05) only for warfarin and direct oral anticoagulants (DOACs). With the exception of ablation, high understanding for a given therapeutic option was not associated with increased use of that therapy at 6 months. CONCLUSIONS: About half of patients with new-onset AF understood the benefits of oral anticoagulant at the time of diagnosis and understanding improved over the first 6 months. However, understanding of AF treatment remains suboptimal at 6 months. Our results suggest a need for ongoing patient education. CLINICAL TRIAL REGISTRATION: Clinicaltrials.gov. Identifier: NCT01701817.

Full Text

Duke Authors

Cited Authors

  • Kaufman, BG; Kim, S; Pieper, K; Allen, LA; Gersh, BJ; Naccarelli, GV; Ezekowitz, MD; Fonarow, GC; Mahaffey, KW; Singer, DE; Chan, PS; Freeman, JV; Ansell, J; Kowey, PR; Rieffel, JA; Piccini, J; Peterson, E; O'Brien, EC

Published Date

  • March 2018

Published In

Volume / Issue

  • 104 / 6

Start / End Page

  • 494 - 501

PubMed ID

  • 28790169

Pubmed Central ID

  • 28790169

Electronic International Standard Serial Number (EISSN)

  • 1468-201X

Digital Object Identifier (DOI)

  • 10.1136/heartjnl-2017-311800


  • eng

Conference Location

  • England